Trader, part of the problem is ADXS said it thought it could potentially get conditional approval for our vet construct by the end of 2015/beginning of 2016, and that we could potentially get the cervical cancer vaccine approved in India without a Phase III. Now O'Connor is saying he thinks we can potentially get conditional approval for our cervical cancer construct in Europe based on our Phase II data before a Phase III is completed. Given his track record to date, the market naturally doubts it.
Market Data 
Markets 
AI
